Review Article Published: 05 July 2024 Towards targeting the breast cancer immune microenvironment Michael A. Harris, Peter Savas, Balaji Virassamy, Megan M. R. O’Malley, Jasmine Kay, Scott N. Mueller, Laura K. Mackay, Roberto Salgado & Sherene Loi Nature Reviews Cancer ...
Pertuzumab in the treatment of HER2-positive breast cancer: 671 an evidence-based review of its safety, efficacy, and place in therapy. Core Evid. 14, 51–70 (2019). Article Google Scholar Agus, D. B. et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor ...
HER2-positive breast cancer is an aggressive subtype of breast cancer with five-year survival rates of 30% for the advanced stage. The development of anti-
It has a reported incidence of 52% but is infrequently associated with breast cancer (0–2.3%). In 2021, a direct-access program to mammography was introduced in Ireland for women over 35 years with mastalgia to avoid the need for clinical review. Methods: A retrospective review of all ...
Contralateral Axillary Lymph NodeMetastasis of Breast Cancer:Retrospective Analysis andLiterature ReviewLiang Zhang 1 , Xin zhao Wang 1 , Chao Li 1 , Qian Yu 2 , Zhaoyun Liu 1 and Zhi yong Yu 1 *1 Department of Breast Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical Un...
(world) of incidence, mortality, and the mortality versus incidence slope value across continents, age groups (before and after 40 years old), and HDI levels; and 2) evaluated the future trends of breast cancer new cases and deaths from 2022 to 2050 and quantified the spearman correlation ...
PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges. Drug Discovery Today. 2019;24:2181–91. Article CAS PubMed Google Scholar López-Knowles E, O’Toole SA, McNeil CM, Millar EKA, Qiu MR, Crea P, et al. PI3K pathway ...
This review provides a full overview of the past and current breast cancer vaccine landscape.Previous article in issue Next article in issue Keywords Cancer Vaccines Immunotherapies Covid-19 Breast cancer Pandemic Immunogenicity Neoantigens 1. Introduction Breast cancer (BC) is the second most ...
MAF amplification increases the risk of breast cancer (BCa) metastasis through mechanisms that are still poorly understood yet have important clinical implications. Oestrogen-receptor-positive (ER+) BCa requires oestrogen for both growth and metastasis, albeit by ill-known mechanisms. Here we integrate...
This review highlights the pivotal signaling pathways in breast cancer and subsequently delves into the molecular distinctions between DCIS and IDC. It offers valuable insights into the biology of the transition from DCIS to IDC, shedding light on notable alterations occurring in tumor cells and the ...